MISC - SHIMODA Kazuya
-
【白血病・リンパ腫 臨床現場で役立つ白血病・リンパ腫の最新の知識】さまざまな白血病・リンパ腫病型における診療のポイント 骨髄増殖性腫瘍の診断と治療
亀田拓郎、下田和哉：
Medical Practice 42 ( 2 ) 219 - 223 2025.2
Publishing type：Article, review, commentary, editorial, etc. (scientific journal)
-
【アンメットニーズに対するJAK阻害薬の可能性】骨髄増殖性腫瘍に対するJAK阻害薬の治療効果
幣光太郎、下田和哉
炎症と免疫 32 ( 2 ) 129 - 132 2024.2
Language：Japanese Publishing type：Article, review, commentary, editorial, etc. (scientific journal)
-
治療法の再整理とアップデートのために 専門家による私の治療 原発性骨髄線維症(PMF)
下田和哉
日本医事新報 ( 5203 ) 34 - 35 2024.1
Publishing type：Article, review, commentary, editorial, etc. (scientific journal)
-
【JAK阻害薬の効果・安全性と展望】骨髄線維症,真性多血症の病態と,JAK阻害薬の効果・安全性・展望
幣光太郎、下田和哉
リウマチ科 70 ( 6 ) 608 - 614 2023.12
Language：Japanese Publishing type：Article, review, commentary, editorial, etc. (scientific journal)
-
【実診療において治療に難渋する造血器腫瘍の病態と新たな治療戦略】二次性骨髄線維症の治療 新規治療薬開発の動向も踏まえて
秋月渓一、下田和哉
血液内科 87 ( 2 ) 193 - 198 2023.8
Publishing type：Rapid communication, short report, research note, etc. (scientific journal)
-
Uchida T., Ueno H., Konagata A., Taniguchi N., Kogo F., Nagatomo Y., Shimizu K., Yamaguchi H., Shimoda K.
Diabetes Therapy 14 ( 6 ) 1075 - 1076 2023.6
Language：English Publishing type：Rapid communication, short report, research note, etc. (scientific journal) Publisher：Diabetes Therapy
-
骨髄増殖性腫瘍に対するインターフェロンα療法
日高智徳、下田和哉：
血液内科 85 ( 6 ) 840 - 845 2022.12
Language：Japanese Publishing type：Article, review, commentary, editorial, etc. (scientific journal)
-
治療法の再整理とアップデートのために 専門家による私の治療 真性多血症(真性赤血球増加症)
下田和哉：
日本医事新報 ( 5140 ) 41 - 42 2022.10
Language：Japanese Publishing type：Article, review, commentary, editorial, etc. (scientific journal)
-
血液内科医のための診断のコツ 骨髄増殖性腫瘍の診断のコツ 疑う症状・検査・診断の手順・ピットフォール
田平優貴、下田和哉：
血液学NAVI 13 11 - 13 2022.10
Language：Japanese
-
Edahiro Y., Ohishi K., Gotoh A., Takenaka K., Shibayama H., Shimizu T., Usuki K., Shimoda K., Ito M., VanWart S.A., Zagrijtschuk O., Qin A., Kawase H., Miyachi N., Sato T., Komatsu N., Kirito K.
International Journal of Hematology 116 ( 4 ) 642 - 643 2022.10
Language：English Publishing type：Rapid communication, short report, research note, etc. (scientific journal) Publisher：International Journal of Hematology
In the original publication of the article, in Table 3 [Summary of adverse events (safety population)], the number of patients who developed suicidal ideation related to study drug (n = 1) was erroneously described, and the correct number is 0 (zero). Therefore, the number of patients who developed psychiatric disorders has also been revised from 2 (6.9) to 1 (3.4). The correct Table 3 is given in this correction.
-
生涯教育シリーズ-102 血液疾患のすべて 白血病と類縁疾患 「骨髄線維症」
下田和哉 他
日本医師会雑誌 151 ( 1 ) S237 - S238 2022.6
Language：Japanese Publishing type：Article, review, commentary, editorial, etc. (scientific journal)
-
臨床各科 難渋症例から学ぶ診療のエッセンス(File 132) 血小板減少、全身浮腫を契機に診断されたTAFRO症候群
久冨木庸子、下田和哉
日本医事新報 2022.3
Language：Japanese Publishing type：Article, review, commentary, editorial, etc. (scientific journal)
-
臨床各科 難渋症例から学ぶ診療のエッセンス(File 125) 血小板減少を契機に診断された急性リンパ性白血病
久冨木庸子、下田和哉
日本医事新報 ( 5097 ) 12 - 13 2022.1
Language：Japanese Publishing type：Article, review, commentary, editorial, etc. (scientific journal)
-
Momelotinib reduces transfusion requirements in patients with myelofibrosis
Mesa R., Oh S.T., Gerds A.T., Gupta V., Catalano J., Cervantes F., Devos T., Hus M., Kiladjian J.J., Lech-Maranda E., McLornan D., Palmer J., Platzbecker U., Treliński J., Shimoda K., Donahue R., D’Hollander K., Kowalski M., Verstovsek S.
Leukemia and Lymphoma 63 ( 7 ) 1718 - 1722 2022
Language：English Publishing type：Rapid communication, short report, research note, etc. (scientific journal) Publisher：Leukemia and Lymphoma
-
Therapeutic Advantage of Tyk2 Inhibition for Treating Autoimmune and Chronic Inflammatory Diseases Reviewed
Ryuta Muromoto, Kazuya Shimoda, Kenji Oritani, Tadashi Matsuda
Biological and Pharmaceutical Bulletin 44 ( 11 ) 1585 - 1592 2021.11
Language：English Publishing type：Article, review, commentary, editorial, etc. (scientific journal)
-
臨床各科 難渋症例から学ぶ診療のエッセンス(File 121) 圧迫骨折を契機に診断された多発性骨髄腫
久冨木庸子、下田和哉
日本医事新報 ( 5091 ) 10 - 11 2021.11
Language：Japanese Publishing type：Article, review, commentary, editorial, etc. (scientific journal)
-
Fibrocytes in primary myelofibrosis Reviewed
Shimoda K., Ozono Y., Shide K.
Oncotarget 12 ( 20 ) 2101 - 2103 2021.9
Language：English Publishing type：Article, review, commentary, editorial, etc. (scientific journal) Publisher：Oncotarget
-
臨床各科 難渋症例から学ぶ診療のエッセンス(File 114) 脳梗塞発症時にみられた血小板数増多
久冨木庸子、下田和哉
日本医事新報 ( 5080 ) 10 - 11 2021.9
Language：Japanese Publishing type：Article, review, commentary, editorial, etc. (scientific journal)
-
Shimosaki S., Nakahata S., Ichikawa T., Kitanaka A., Kameda T., Hidaka T., Kubuki Y., Kurosawa G., Zhang L., Sudo Y., Shimoda K., Morishita K.
Biochemical and Biophysical Research Communications 530 ( 2 ) 486 2020.9
Language：English Publishing type：Article, review, commentary, editorial, etc. (scientific journal) Publisher：Biochemical and Biophysical Research Communications
The authors regret that the day of antibody injection for NOG mice subcutaneously transplanted with MT-2 or HH must be corrected from “every 3 days” to “every 3–4 days” in the part of “Supplementary materials and methods”. The authors also regret that the day of antibody injection for NOG mice subcutaneously transplanted with MT-2 or Su9T01 must be corrected from “two times per week for 2 weeks” to “on day 1, day 8, day 15, and day 21 post-cell injection” in the part of “Supplementary materials and methods”. These corrections do not change the conclusions of this manuscript. The authors would like to apologise for any inconvenience caused. The correct supplementary materials and methods. In vivo experimental therapy studies. Six-to eight-week-old female NOD/Shi-scid/IL-2Rγnull (NOG) or SCID mice (CLEA Japan) were given a single subcutaneous injection of 2 × 106 MT-2 cells or HH cells suspended in 100 μL PBS-diluted matrigel (BD Biosciences). When the average tumor size reached an approximate volume of 100–150 mm3, the mice were intravenously injected with either PBS, mogamulizumab, or the JST-TFR09 antibody at doses of 10 mg/kg (MT-2) or 20 mg/kg (HH) body weight 4–5 times every 3–4 days. The length and width of each tumor were measured with a caliper twice per week and used to calculate the tumor volume (length × width2/2). For Kaplan-Meier survival analysis of mice, NOG mice were given a single intravenous injection of 1 × 106 MT-2 or Su9T01 cells suspended in 100 μL PBS. At 3 days after inoculation of ATLL cells, the mice were intravenously injected with either PBS or JST-TFR09 on day 1, day 8, day 15, and day 21 post-cell injection. The survival rate of mice was observed for a period of 100 days. The authors would like to apologise for any inconvenience caused.
-
Shimoda K,Takahashi N, Kirito K, Iriyama N, Kawaguchi T, Kizaki M.
International Journal of Hematology 112 ( 3 ) 268 - 291 2020.9
Language：English Publishing type：Article, review, commentary, editorial, etc. (scientific journal)